Fiche publication
Date publication
janvier 2021
Journal
Clinical pharmacology : advances and applications
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel
,
Pr VERGES Bruno
Tous les auteurs :
Rouland A, Bouillet B, Legris P, Simoneau I, Petit JM, Vergès B
Lien Pubmed
Résumé
Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a first-line treatment but can be poorly tolerated because of its side effects, and therapeutic failure is possible. Somatostatin analogues have limited efficacy because of their poor affinity to somatostatin (SST) receptors. Pasireotide is a somatostatin analogue with a much higher affinity to SST receptors, especially SST5, and it could thus be more efficient for treating nesidioblastosis-related hypoglycemia.
Mots clés
diazoxide, hypoglycemia, nesidioblastosis, pasireotide LAR
Référence
Clin Pharmacol. 2021 ;13:33-37
